In a Financial Times article analyzing the decline in dealmaking following the J.P. Morgan Healthcare Conference, life sciences partner Michael Beauvais explained that regulatory scrutiny has raised transactional risk in the life sciences sector.
Michael notes the Federal Trade Commission is being aggressive in examining some transactions and looking at private equity buyers that are serial acquirers. “This is causing concern for companies because it can be disastrous if a publicly announced deal does not progress, particularly for a target,” said Michael.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.